Gilead Sciences has battled back from a pipeline disappointment last year to its highest stock price in nearly a decade.

Scientists have been excited about the discovery of HIV-1 broadly neutralizing antibodies ... role in his overly ambitious plans to excise $2 trillion from the federal government's budget as ...

A new rule requires insurers to improve coverage of PrEP, which can prevent HIV, but Georgians face challenges getting the ...

The UK government has announced that it is renewing funding for the public health campaign HIV Prevention England for another year as part of efforts to end HIV transmission by 2030. The programme, ...

An overall increase in life expectancy was observed across all individuals living with HIV but disparities between gender groups persist.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

Adults in Tanzania living with HIV and taking tenofovir have a higher rate of chronic kidney disease vs. those without the ...

The head of the U.N. AIDS agency said Monday the number of new HIV infections could jump more than six times by 2029 if ...

Full-year sales reached $26.8 billion, driven by robust performance across HIV, oncology, and liver disease portfolios. HIV sales grew 8% year-over-year to $19.6 billion in 2024, exceeding ...

Donald Trump's decision to cut vital aid has stunned health officials and charities working to fight HIV and AIDS. One told ...